Scholar Rock develops biologic and small‑molecule agents that modulate growth‑factor proteins before activation, aiming to intervene early in disease pathways. Its platform supports a pipeline across neuromuscular, cardiometabolic, immuno‑oncology, and fibrotic indications, with integrated preclinical, IND‑enabling, and clinical development and collaborations for expanded‑access studies.
Funding
$300M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with serious neuromuscular, cardiometabolic, immuno‑oncology, and fibrotic diseases often lack therapies that address the underlying molecular drivers. Existing drugs typically intervene after growth‑factor pathways are already activated, limiting efficacy and durability of response. This leaves a therapeutic gap for conditions where dysregulated growth‑factor signaling is a primary disease mechanism.
Solution
Scholar Rock applies a proprietary platform that selectively targets protein growth factors before they become activated, effectively “shutting off the water supply” at the source of disease signaling. By designing molecules that modulate these upstream proteins, the company creates investigational therapies that can intervene earlier in the disease cascade. The platform is applied across multiple therapeutic areas, including spinal muscular atrophy, cardiometabolic disorders, solid‑tumor immuno‑oncology, and fibrotic diseases. Each candidate progresses through preclinical validation, IND‑enabling studies, and clinical trials under a unified scientific framework. The company also supports expanded‑access programs and investigator‑initiated studies to accelerate patient access and generate real‑world evidence. Results are communicated through peer‑reviewed publications and regulatory filings, ensuring transparency and scientific rigor.
Target Audience
The primary customers are patients with serious growth‑factor‑driven diseases and the healthcare providers who prescribe disease‑modifying therapies, including neurologists, cardiologists, oncologists, and pulmonologists. Additionally, research institutions and biotech partners seeking to co‑develop growth‑factor‑targeted agents are key stakeholders.
Features
- Targeted modulation of growth‑factor proteins prior to activation using proprietary biologic and small‑molecule designs
- Platform‑driven pipeline spanning neuromuscular, cardiometabolic, immuno‑oncology, and fibrotic indications
- Integrated preclinical and clinical development workflow with IND‑enabling toxicology, pharmacokinetics, and biomarker strategies
- Collaboration framework for investigator‑initiated studies and expanded‑access pathways to broaden patient enrollment
- Robust data generation pipeline supporting regulatory submissions and peer‑reviewed publications
- Scalable manufacturing strategy leveraging third‑party CMO networks for GMP‑grade product supply
- Secure digital portal for HCPs to access trial information, dosing protocols, and safety monitoring tools